Late administration of a specific COX-2 inhibitor does not treat and/or prevent progression of gastric tumors in rats submitted to duodenogastric reflux procedure

Rodrigues, Paulo Antônio; Naresse, Luiz Eduardo; Rodrigues, Maria Aparecida Marchesan; Kobayasi, Shoiti.
Acta cir. bras ; 28(6): 453-457, June 2013. ilus, tab
Artículo en Inglés | LILACS | ID: lil-675581

Documentos relacionados

  1. Molecular pathogenesis and emerging targets of gastric adenocarcinoma.
  2. Clear cell carcinoma of the stomach: a rare tumor variant imparting poor prognosis.
  3. Intensifying supportive care is associated with improved survival in gastric cancer patients with malignant ascites.
  4. Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma.
  5. Sintilimab Plus Apatinib and Chemotherapy as Second­/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial.
  6. Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial.
  7. Effect of preoperative chemotherapy on the histopathological classification of gastric cancer.
  8. Stroma AReactive Invasion Front Areas (SARIFA) improves prognostic risk stratification of perioperative chemotherapy treated oesophagogastric cancer patients from the MAGIC and the ST03 trial.
  9. [A Case of Conversion Surgery for Stage Ⅳ ATP-Producing Gastric Cancer with Distant Metastasis].
  10. Postoperative Complications After Neoadjuvant Chemotherapy Versus Upfront Surgery in Gastric Adenocarcinoma: A Population-Based Nationwide Study in Finland.